Leadless Pacemaker Redesign Needed After Early Dislodgement Issues at Heart Rhythm 2026

A novel leadless pacemaker designed to deliver pacing directly to the left bundle branch area of the heart has shown promise in early clinical testing, but ongoing technical challenges have prompted a redesign effort by its developers. Presented at the Heart Rhythm 2026 conference, the first-in-human study results for the Aveir CSP (Conduction System Pacing) leadless pacemaker from Abbott indicate that the device achieved successful pacing parameters in five of ten patients at one month post-implant. However, dislodgement issues observed during the trial have led Abbott to initiate a redesign to improve device stability and reliability.

The Aveir CSP system represents a significant advance in cardiac pacing technology, as it is the first leadless pacemaker to target the left bundle branch area, a region critical for coordinated heart contractions. Traditional pacemakers often rely on transvenous leads, which can be associated with risks such as lead failure, infection, and the need for future lead replacements. By eliminating these leads, leadless pacemakers aim to reduce complications and improve patient outcomes, particularly for those with heart failure or conduction system disorders.

Vivek Y. Reddy, MD, director of cardiac arrhythmia services at Mount Sinai Hospital and the Mount Sinai Health System, presented the findings at Heart Rhythm 2026. Dr. Reddy’s team had previously reported at Heart Rhythm 2025 that the device successfully achieved left bundle branch area pacing capture in five of ten patients who underwent successful implantation. This initial success underscored the potential of the technology to mimic the heart’s natural electrical conduction, which is particularly beneficial for patients with left bundle branch block and heart failure with reduced ejection fraction.

Technical Challenges and the Path Forward

Despite the early promise, the study encountered dislodgement issues that have become a focal point for Abbott’s ongoing efforts. According to the company and clinical investigators, these challenges highlight the need for further refinement in device design and implantation techniques. Abbott has since announced a redesign effort aimed at enhancing the stability and long-term performance of the leadless pacemaker.

The importance of conduction system pacing, including left bundle branch area pacing, has been increasingly recognized in the cardiology community. Recent clinical trials, such as HeartSync-LBBP and PhysioSync-HF, have explored the comparative effectiveness of conduction system pacing versus biventricular pacing in patients with heart failure and left bundle branch block. While these studies have yielded mixed results, they have collectively contributed to a growing body of evidence supporting the potential benefits of conduction system pacing for improving heart function and patient quality of life.

Broader Implications for Cardiac Care

The development of leadless conduction system pacemakers could revolutionize the treatment of heart rhythm disorders, offering a less invasive alternative to traditional pacemakers. By targeting the left bundle branch area, these devices aim to restore more natural heart contractions, which may lead to better clinical outcomes for patients with heart failure and conduction abnormalities.

However, the journey from initial clinical feasibility to widespread adoption is fraught with technical and regulatory hurdles. The observed dislodgement issues serve as a reminder that innovation in medical devices requires rigorous testing and iterative improvement. As Abbott and other developers continue to refine their designs, the cardiac community remains optimistic about the potential of leadless pacemakers to transform the management of heart rhythm disorders.

For patients and clinicians alike, the Aveir CSP study results offer a glimpse into the future of cardiac pacing, where less invasive, more reliable, and more effective treatments may soon become the standard of care. As research progresses, the focus will remain on ensuring that these advanced technologies deliver on their promise of improved patient outcomes and quality of life.

For more information on conduction system pacing and related clinical trials, readers are encouraged to consult the latest findings from peer-reviewed journals and reputable medical organizations.